Pausing hormone therapy after breast cancer for pregnancy; Immunogen ovarian cancer drug shown to extend patients’ lives

Plus: Experts decry outdated CAR-T precautions and debate the benefits of liquid biopsies to catch cancer

May 5, 2023 Check out STAT+

Sponsored By

Adobe After early-stage breast cancer, interrupting endocrine therapy to become pregnant didn't raise risk of recurrence New research suggests that women who've been treated for hormone-sensitive breast cancer can interrupt endocrine therapy to attempt pregnancy. By Elizabeth Cooney STAT+ | Immunogen ovarian cancer drug shown to extend patients' lives The company said the data make Elahere the first drug to show a survival benefit in patients who progress after platinum chemotherapy. By Jason Mast STAT+ | CAR-T research is flourishing but is hampered by outdated precautions, experts say Experts in the technology that has changed cancer treatment say China is starting to pull ahead because of less red tape. By Angus Chen Sarah Gonzalez for STAT 'Are we better off with the information?': Experts spar over the benefits of liquid biopsy to catch cancer Liquid biopsy making it possible to detect cancer earlier than ever — but the field is still divided on whether it's ready for prime time.  By Brittany Trang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser